43 Proteomics, Genomics & Microarrays Ultra-high performance CRISPR Cas12a Enzyme Launched
Integrated DNA Technologies (IDT) releases its latest CRISPR enzyme Alt-R® Cas12a (Cpf1) Ultra. Cas12a Ultra is a powerful addition to IDT’s Alt-R CRISPR enzyme arsenal - its vastly improved performance makes it easier to achieve precision genome editing at new sites across genomes.
Publication of the Cas12a system in 2015 generated considerable interest among researchers seeking new enzymes for genome editing experiments, particularly due to its unique PAM site (‘TTTV’) that greatly expanded the number of potential editing sites in the genome beyond that of Cas9 (‘NGG’). IDT developed a novel mutant of the Acidaminococcus sp. BV3L6 Cas12a (Cpf1), called Cas12a Ultra. The new mutant enzyme has enhanced editing activity, reaching or exceeding the performance of Cas9. The new Cas12a Ultra also retains activity across a wider temperature range than the wild type enzyme, making it useful for genome editing in additional organisms, including plants.
Editas Medicine, a leading company developing genome editing medicines, recognised the potential advantages of the newly discovered Cas12a (also known as Cpf1) system and obtained an exclusive license from the Broad Institute, Inc, acting on behalf of itself and the President and Fellows of Harvard College, the Massachusetts Institute of Technology, Wageningen University, and the University of Tokyo in 2016 for human therapeutics. Editas Medicine also signed an exclusive license from IDT for use of Cas12a Ultra in human therapeutic applications, several months prior to IDT’s commercial release of the product for research use.
IDT’s Alt-R Cas12a (Cpf1) Ultra is a first addition to the genome editing toolbox that offers the same efficiency and versatility as Cas9. The new tool will find equal utility for both knock-out as well as knock-in applications, in fields ranging from basic research cell engineering to medical gene therapy to agricultural biotechnology. By incorporating Cas12a (Cpf1) Ultra from IDT into their research plan, scientists will also benefit from the exceptional quality of IDT’s recombinant genome editing protein manufacturing, high throughput guide RNA synthesis capacity, and best-in-class technical support.
49387pr@reply-direct.com
New Tissue Microarrays Conform with FDA Standards
Amsbio offers an unmatched portfolio of over 2000 tissue microarrays (TMAs), one of the best sample formats for rapid detection of cellular localization of RNA and protein expression.
Recently Amsbio introduced US Food & Drug Administration (FDA) standard TMAs for human, mouse and rat to its portfolio. Designed in close conformance with FDA guidelines, this range meets the requirements for tissue cross-reactivity studies required for therapeutic and diagnostic antibody and antibody-like molecules validation. Each array slide features the FDA recommended list of normal tissue types in triplicate, allowing the identification of off-target binding and on-target binding that has not been previously identified.
Tissue microarray slides offer a rapid and cost-effective direct method for the validation of biological targets in multiple tissue samples. Parallel analysis of multiple specimens reduces operating times, conserves reagents and facilitates high-throughput molecular analysis of tissues.
The new FDA standard TMAs form part of Amsbio’s broad collection of normal and tumour TMAs available in FFPE and frozen formats. Produced using high-quality tissue samples selected by board-certified pathologists, TMAs are a remarkable tool with a range of potential applications in basic research, prognostic oncology and drug discovery.
49330pr@reply-direct.com
Custom Cell Biology Services Offering Unique Manufacturing and Testing Capabilities Introduced
Lonza has introduced CellBio Services, a comprehensive portfolio of unique, custom solutions designed to meet specific, individual research application needs. Researchers across pharmaceutical and contract manufacturing organisations can now choose from an extensive range of services, including cell-line expansion and banking, media production, cell isolation, cell characterisation, transfection services, and 3-dimensional (3D) cell-culture services.
“For many years we’ve been leading the cell research market, with a broad offering of high-quality primary cells, media, reagents and devices,” said Andrew Winner, Product Manager for CellBio Services at Lonza Pharma Biotech & Nutrition. “CellBio Services has been established to expand this offering beyond the standard catalogue products and beyond what’s currently available on the market. Our customers can now benefit from unique manufacturing and testing capabilities, as well as Lonza’s access to the broadest tissue inventories, to unlock the next level of their research options.”
Lonza’s all-inclusive CellBio Services offering comprises: cell-line expansion and banking - cell lines can be expanded up to 10e10 and the cells can be cryopreserved in the preferred format; media production - manipulation of Lonza’s catalogue media products or production of new media, either in liquid or powder format; cell isolation - from a variety of tissues, including human, primate, porcine, canine, feline and murine; cell characterisation - development of cell-based assays for functional testing of recombinant proteins and small molecules; generation of recombinant cell lines - fast and convenient creation of recombinant cell lines overexpressing the gene of interest; 3D cell-culture services - the patented RAFT™ System is used to generate custom 3D cell culture systems, such as co-cultures and barrier models.
48789pr@reply-direct.com
The Spotlight could be on you! Check out our Media Information
Pack for further details and send your Press Releases to
pr@intlabmate.com
New Catalogue of Infectious Disease Antibodies and Antigens
ViroStat announces the release of its 2019 Catalogue of Infectious Disease Antibodies and Antigens.
This new catalogue contains over 750 Products including: MONOTOPE™ Mouse Monoclonal Antibodies; MabyRab™ Rabbit Monoclonal Antibodies; OMNITOPE™ Polyclonal Antibodies; Recombinant Antigens.
ViroStat is a primary manufacturer, supplying infectious disease reagents to researchers and rapid test manufacturers since 1985.
Contact ViroStat for your free copy of the new catalogue or view and download it online. More information online:
www.virostat-inc.com
49166pr@reply-direct.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60
